We are Committed to Life

Q2/26 demonstrates Fresenius’ structural transformation, consistently turning operational momentum into earnings growth and delivering the highest capital returns in the decade. Outstanding EPS performance on the back of strong operating results of the core businesses. FY/26 guidance upgraded to 10% to 15% for constant currency Core EPS growth (previous 5% to 10%).

Q1/26 builds further on strong momentum: Continued operating strength of core businesses with solid topline development and excellent Core EPS growth; FY/26 guidance reconfirmed

中国北京，2026年3月3日 —— 作为全球医疗健康集团费森尤斯（Fresenius）旗下重要成员、提供关键药品与医疗技术领域的领先企业，费森尤斯卡比（Fresenius Kabi）今日宣布，其在华控股合资公司费森尤斯卡比华瑞制药有限公司（以下简称“费卡华瑞”）旗下原研进口ω-3鱼油脂肪乳注射液尤文®（Omegaven）儿科适应症[1]已获得国家药品监督管理局（NMPA）批准。